Mayne Pharma Group Limited

Equities

MYX

AU000000MYX0

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
7.24 AUD +0.28% Intraday chart for Mayne Pharma Group Limited +3.87% +17.72%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% MT
Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024
Mayne Pharma Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million CI
Transcript : Mayne Pharma Group Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM
Mayne Pharma Group Limited Approves Election of Anne Lockwood CI
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill MT
Mayne Pharma Gets Additional US Patent for Contraceptive MT
Mayne Pharma Gets Go-Ahead for Resignation of EY as Auditor MT
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call
Mayne Pharma Acquires Dermatological Medication MT
Mayne Pharma Group Limited completed the acquisition of Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC. CI
Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million. CI
Australian Shares Rebound Ahead of Central Bank Policy Meeting MT
Mayne Pharma Group Purchasing Global Rights to Topical Treatment RHOFADE MT
Transcript : Mayne Pharma Group Limited, 2023 Earnings Call, Aug 31, 2023
Tranche Update on Mayne Pharma Group Limited's Equity Buyback Plan announced on May 10, 2023. CI
Mayne Pharma Group Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Lupin Gets US FDA Nod for Doxycycline Hyclate Delayed-Release Tablets MT
Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023 CI
Mithra Pharmaceuticals Cuts Mayne Pharma Group Stake to 4.96% MT
An unknown buyer acquired a 4.97% stake in Mayne Pharma Group Limited from Estetra Srl for AUD 16 million. CI
Transcript : Mayne Pharma Group Limited - Special Call
Chart Mayne Pharma Group Limited
More charts
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.24 AUD
Average target price
7.035 AUD
Spread / Average Target
-2.83%
Consensus